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Abstract The RET gene is expressed with high tissue and
stage speci¢city during development. Understanding its tran-
scriptional regulation might provide new clues to clarify devel-
opmental mechanisms. Here we show that the histone deacetyl-
ase inhibitor sodium butyrate (NaB) increases RET transcrip-
tion in cells displaying low levels of its mRNA, while it has no
e¡ect in cells expressing at high levels. Chromatin immunopre-
cipitation (ChIP) experiments showed increased histone acety-
lation within the same region, in particular the Sox10^Pax3
enhancer site, due to NaB. Accordingly, ChIP showed di¡erent
acetylation levels at the Sox10^Pax3 site associated with cell-
line speci¢c RET transcription rates. Concluding, chromatin
acetylation targeted to functional sequences in the RET regu-
latory region may control its transcription. . 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Acetylation of core histone tails is now recognized as a
conserved mechanism modulating gene expression. It is able
to relax higher order chromatin, to promote factor binding to
DNA and to recruit unique biological complexes that mediate
downstream functions [1]. Switch from inactive to active chro-
matin is often accompanied by histone hyperacetylation of
critical sites in gene regulatory regions [2,3]. The antagonistic
activities of histone acetyltransferases and histone deacetylases
(HDACs) control the nuclear steady-state balance of this co-
valent modi¢cation [1]. Histone hyperacetylation can be ac-
complished, in vitro, by treating cells with inhibitors of cellu-
lar HDACs [4] such as sodium butyrate (NaB). These drugs
selectively a¡ect the transcription of speci¢c genes [4]. Chro-
matin immunoprecipitation (ChIP) experiments have shown a
direct e¡ect of these molecules on the acetylation status of
their target genes’ regulatory regions [5].
The RET proto-oncogene encodes a tyrosine kinase recep-
tor predominantly expressed in the developing embryo [6].
Germline RET mutations are associated with both Hirsch-
sprung disease (HSCR) and inherited cancer syndromes: mul-
tiple endocrine neoplasia types 2A and 2B (MEN2A,
MEN2B) and familial medullary thyroid carcinoma (MTC)
[7]. While MEN2 syndromes are due to constitutive activation
of the Ret receptor, HSCR phenotype is caused by haploin-
su⁄ciency or loss of function of the RET gene. However, a
proportion of such genetic disorders is not associated with
mutations in the RET coding sequence, suggesting the possi-
ble involvement of expression defects caused by alteration of
regulatory sequences. Accordingly, RET expression or over-
expression has been reported in sporadic pheochromocytomas
[8] and in head and neck carcinomas [9], in the absence of
mutations in the coding region. Finally, in HSCR disease,
defective RET expression has also been suggested to contrib-
ute in some cases to the disease phenotype [10,11]. Thus,
understanding the regulation of RET expression will provide
new clues to the study of gene-related diseases.
Previously, we analyzed RET mRNA expression, transcrip-
tion rate and promoter activity in di¡erent cell lines [12^14].
We showed that this gene transcription is cell-line speci¢c.
The functional domains of RET minimal promoter were iden-
ti¢ed and Sp1 was shown to be the main positive regulator of
the promoter function. However, transfection experiments in
cell lines expressing di¡erent levels of RET mRNA did not
show promoter activities consistent with endogenous gene ex-
pression, thus raising the question of how the regulated pat-
tern of RET transcription is achieved at the molecular level.
In this report, we analyzed the e¡ect of histone acetylation
on RET expression in di¡erent, RET-positive, human cell
lines. We show that NaB increases RET transcription and
promotes hyperacetylation of the gene upstream region. In
addition, chromatin acetylation targeted to regulatory sequen-
ces in the same region contributes to control cell-line speci¢c
RET transcription.
2. Materials and methods
2.1. Plasmids
Mae3PCAT has been described previously [13]. Bas+6.5VpCAT
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contains the 6557 bp fragment of the commercially available VDNA
HindIII digest (New England BioLabs, Beverly, MA, USA), cloned
into acceptor HindIII sites of the pCATBasic empty vector (Promega
Italia, Milan, Italy). The RET promoter sequence referred to in this
report corresponds to GenBank accession number AF03214.
2.2. Cells and NaB treatment
Human neuroblastoma IMR32 and MTC-TT cells were grown as
already described [14]. NaB (Sigma^Aldrich, Milan, Italy) was dis-
solved in water (1 M stock solution), and delivered to cells at a ¢nal
concentration of 5 mM. Treatment was performed overnight.
2.3. Transfection and CAT assay
Transfection was performed with polyethylenimine (800K, Sigma^
Aldrich) as previously described [14]. Upon transfection and NaB
treatment, CAT assays were performed [14]. Each transfection was
performed with duplicate samples and repeated at least three times.
2.4. Nuclear run-on assay
Nuclei were prepared from 30^80U106 cells [15]. Biotin-16-UTP
(Roche Molecular Biochemicals, Milan, Italy) was added to a stan-
dard reaction mix and Dynabeads M-280 (Dynal, Oslo, Norway) were
used to capture the labeled molecules from puri¢ed nuclear RNA,
as described [15]. Beads were resuspended in DEPC-treated water
(30 Wl).
2.5. Semi-quantitative RT-PCR
Random hexamer primed cDNA was prepared from 3^10 Wl run-on
RNA or 500 ng total RNA. The £uorescence-based semi-quantitative
PCR method was already described in [15]. In both total RNA and
run-on analysis, di¡erent R-values were determined from independent
treatments and, for each treatment, from independent sets of PCR
reactions.
2.6. ChIP
IMR32 and MTC-TT cells were labeled for 24 h with 0.5 WCi/ml
[3H]thymidine (Amersham Pharmacia Biotech, Milan, Italy), treated
with 5 mM NaB, collected and washed in PBS/5 mM NaB to prevent
histone deacetylation. Isolation of nuclei from 2.5U108 cells and di-
gestion with micrococcal nuclease (Amersham Pharmacia Biotech,
Italy) were performed, with minor modi¢cations, as described in
[16]. Chromatin was immunoprecipitated with antibodies against hy-
peracetylated histone H4 (Upstate Biotechnology, Dundee, UK) as
reported by Johnson [17]. DNA was isolated from the antibody-
bound (i.e. highly acetylated), unbound (i.e. underacetylated) and in-
put chromatin fractions by phenol/chloroform extraction. The
[3H]thymidine incorporation was determined by scintillation counting.
Equal amounts of DNA from each fraction, based on [3H]thymidine
content, were used for semi-quantitative PCR.
Semi-quantitative PCR analysis was performed from serially diluted
DNA samples [15]. PCR reactions were run on a 1.5% agarose gel
with SYBR Gold Nucleic Acid Gel Stain (Molecular Probes, Eugene,
OR, USA) and analyzed on Storm 860 (Amersham Pharmacia Bio-
tech, Italy) with the ImageQuant software. A 700 bp fragment, con-
taining both Sox10 and Pax3 binding sites, was obtained with prim-
ers: SPX1F (5P-TGTGGGGACATGGAAAACTG-3P) and SPX1R
(5P-TGGCATTCCTGGAACTGCTG-3P). A 402 bp fragment, includ-
ing the minimal promoter sequence, was ampli¢ed with Prom1F
(5P-CCCGCACTGAGCTCCTAC-3P) and Prom1R (5P-GGACGT-
CGCCTTCGCCAT-3P). Primers SSCP12F (5P-TCTTCTCCCCCT-
TCCCTCAT-3P) and SSCP12R (5P-GCCCCGGAGACTCCCCCA-
G-3P) were used to amplify a 225 bp fragment including RET exon
12 [18]. The human housekeeping L-actin gene was ampli¢ed with the
forward primer 1F (5P-TCACCCACACTGTGCCCATCTACGA-3P)
and the reverse primer 1C (5P-CAGCGGAACCGCTCATTGC-
CAATGG-3P) to yield a 297 bp fragment.
2.7. Statistical analysis
In all experiments presented in this report, signi¢cance of results
was determined by Student’s t-test, available on-line (Tools for Sci-
ence, Statistics site, at www.physics.csbsju.edu/stats).
3. Results
3.1. Activation of RET expression and transcription in two
human cell lines
In order to determine whether histone acetylation can mod-
ulate RET expression, we used the HDACs inhibitor NaB to
convey histone hyperacetylation in two human cell lines,
showing di¡erent endogenous amounts of the gene mRNA,
as we previously reported [14]. RET was shown to be expressed
at high levels in MTC-TT cells, derived from MTC, while only
a low level was detected in neuroblastoma IMR32 cells.
Upon treatment, we collected total RNA and quanti¢ed
RET expression using a £uorescence-based semi-quantitative
PCR [15]. As depicted in Fig. 1A, inhibiting cellular HDACs
resulted in a signi¢cant up-regulation of RET mRNA in
IMR32 cells while it had no e¡ect on MTC-TT cells.
To test if NaB directly a¡ects the gene transcription, we
collected intact nuclei from IMR32 cells and performed the
nuclear run-on assay [15]. Fig. 1B shows a representative sin-
gle point ampli¢cation of four independent run-on experi-
ments. Statistical analysis indicated a 10-fold activation of
RET expression in IMR32 treated nuclei (P6 0.01, after
four independent experiments). The observed activation was
even more evident as compared to the total RNA.
Fig. 1. Up-regulation of RET expression and transcription in RET
mRNA-positive cells. The IMR32 and MTC-TT cells were treated
with 5 mM NaB and the RET gene expression and transcription
rate assessed as described in the text. A: The histogram depicts
RET expression values of total RNA from treated (NaB) relative to
untreated (UN) cells. Mean values and error bars are referred to
eight independent calculations. Asterisks indicate signi¢cance of re-
sults: three asterisks indicate P6 0.01. B: Single point ampli¢cation
of both RET and the housekeeping G3PDH gene, performed using
nuclear run-on RNA derived from untreated (UN) and 5 mM NaB-
treated (NaB) cells.
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3.2. Sensitivity of RET promoter region to NaB
Chromatin assembly has also been shown to take place on
plasmid DNA transfected into cells [19,20]. Therefore, sensi-
tivity of promoters to histone acetylation can be assessed on
transfected DNA [5,21]. To test whether NaB treatment was
able to relax chromatin of the plasmid containing 5 kbp of the
RET upstream region, we transfected IMR32 cells with the
Mae3PCAT plasmid (35057/+53) [14]. To verify if the ob-
served e¡ects were sequence speci¢c, the RET region was sub-
stituted by phage VDNA (a 6.5 kbp HindIII fragment) in a
control plasmid: Bas+6.5VpCAT. CAT activities were mea-
sured in untreated and NaB-treated cells. NaB dramatically
activated the promoter function of Mae3PCAT (Fig. 2),
whereas substitution of the RET sequences with phage
VDNA was unable to reproduce such an e¡ect. Thus, the
RET region analyzed is speci¢cally sensitive to NaB.
3.3. NaB determines histone hyperacetylation at
the Sox10^Pax3 enhancer site
We performed the ChIP assay on NaB-treated and un-
treated IMR32 cells to test whether NaB had a direct e¡ect
on the acetylation level of histones within RET regulatory
sequences. Antibodies against tetra-acetylated histone H4
were used to collect hyperacetylated chromatin and the asso-
ciated genomic DNA. Antibody-bound (i.e. highly acetylated)
and unbound (i.e. underacetylated) fractions were analyzed
for relevant sequences by semi-quantitative PCR. Quanti¢ca-
tion was performed for selected sequences located inside the
5 kbp 5P-RET £anking region previously shown to be crucial
for expression. The minimal promoter (3147/+53), containing
four overlapping Sp1 sites [14,22], and an enhancer element
consisting of the Sox10 and Pax3 binding sites (33996/33390)
[23] were tested. Finally, we analyzed RET exon 12, as a
control sequence within the gene genomic region, likely to
be una¡ected by NaB.
Due to its GC-rich sequences, the RET minimal promoter
signal, quanti¢ed by PCR, was also con¢rmed by ¢lter hy-
bridization (data not shown). In each case, normalization of
ChIP sample values was performed quantifying the L-actin
housekeeping gene, taken as the reference assay for associa-
tion between histones and DNA.
NaB treatment signi¢cantly enhances the acetylation level
Fig. 2. NaB sensitivity of RET promoter region. IMR32 cells were transfected with the indicated constructs. After NaB treatment, cells were
collected and CAT reactions performed. CAT activities were normalized to protein content and expressed as activity obtained from NaB-
treated cells (dark bars) relative to untreated cells (light bars). Means and mean standard errors are given for at least three separate experi-
ments. Three asterisks indicate P6 0.01.
C
Fig. 3. Quanti¢cation of ampli¢cation products from ChIP samples:
NaB-treated IMR32 cells. The RET genomic region (not to scale) is
represented in the lower panel. Horizontal bars represent the se-
quences analyzed in ChIP assays. Bars in the upper panel indicate
the relative histone H4 acetylation level within the sequences ana-
lyzed by semi-quantitative PCR. Calculation was performed as fol-
lows: the ratio of antibody-bound/unbound signals was determined
and normalized to the L-actin ratio and total [3H]thymidine content.
Dark bars represent values obtained from NaB-treated cells while
light bars those from untreated cells. Means and mean standard er-
rors are given for at least three separate experiments. Three aster-
isks indicate P6 0.01.
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of histones associated with the Sox10^Pax3 sequence (Fig. 3).
The acetylation level of the minimal promoter fragment was
not signi¢cantly a¡ected by NaB. As expected, the exon 12
signal detected from treated cells was comparable to control.
3.4. Endogenous association of hyperacetylated histones with
RET upstream region
ChIP was then performed on untreated IMR32 and MTC-
TT cells to determine whether endogenous levels of acetyla-
tion were related to physiological modulation of RET expres-
sion. We tested the above-described sequences for enrichment
in the antibody-bound DNA fraction.
Our results indicate that Sox10^Pax3 enhancer was signi¢-
cantly enriched in histone acetylation in MTC-TT cells as
compared to IMR32 cells (Fig. 4). The minimal promoter
also appeared to be di¡erentially acetylated. The di¡erence
between the two cell lines (Fig. 4), although detectable, did
not reach statistical signi¢cance in our PCR experiments but it
was con¢rmed by ¢lter hybridization (data not shown). No
di¡erences were seen both in the L-actin gene and RET exon
12 sequences.
4. Discussion
Chromatin structure is a major determinant of transcrip-
tion, activation of gene expression being dependent on the
interplay of several nucleosome remodeling activities [1,2].
The present work was undertaken to establish a model for
studying the RET gene transcription and the possible role of
histone acetylation on RNA production.
NaB treatment, used to convey histone hyperacetylation,
was able to activate RET expression and increase the tran-
scription in IMR32 cells displaying low levels of its mRNA,
supporting a model in which NaB directly promotes RET
transcription. Transient transfections con¢rmed that RET up-
stream sequences are speci¢cally sensitive to NaB. As further
con¢rmation, we have recently shown that NaB also stimu-
lates a detectable level of transcription in RET-negative lym-
phoblastoid cells (P. Griseri et al., submitted). We did not
observe an increase of RET transcription mediated by NaB
in MTC-TT cells. These data can be explained by their high
levels of RET mRNA, re£ecting that histone acetylation at
crucial sites might already have reached a plateau level.
ChIP with antibodies against acetylated histone H4 was
performed to test whether NaB had a direct e¡ect on the
acetylation status of the RET upstream region. This was par-
ticularly evident at the enhancer element consisting of the
Sox10 and Pax3 binding sites [23], indicating that this site is
prone to enrichment in histone acetylation level resulting from
treatment, and it is important for chromatin acetylation-de-
pendent transcriptional regulation.
ChIP was also performed on untreated IMR32 and MTC-
TT cells to determine the endogenous levels of acetylation in
the RET upstream region. In particular, we found that tran-
scription may be controlled by targeted chromatin acetylation
in the Sox10^Pax3 enhancer, suggesting a ¢ne regulation of
these two transcription factors. One hypothesis for the role of
these proteins is that they might take part in an activating
multimeric complex, including histone-acetylating activities.
These data further strengthen the indication that the acetyla-
tion level within the RET 5P £anking region correlates with
endogenous gene expression.
The minimal promoter also appears to display di¡erent
levels of histone acetylation in di¡erent cell lines, thus indicat-
ing that Sp1 may contribute to cell-line speci¢c acetylation.
However, the minimal promoter is not a¡ected by NaB, thus
suggesting that the Sp1 sites are not involved in the up-regu-
lation of RET expression induced by the treatment. Speci¢c
transcription factors can confer distinct patterns of histone
acetylation on target promoters or promoter regions [24]. In
this line, we can envisage a di¡erential responsiveness or an
insensitivity of the Sp1 DNA sequences to a particular deace-
tylase inhibitor, such as NaB, as recently reported [25].
RET is one of the ¢rst transcribed genes in the pericentro-
meric region of chromosome 10 [26]. This region is particu-
larly prone to rearrangements, as deduced from changes that
have occurred during evolution [26]. Therefore, rearrange-
ments in the pericentromeric region, involving for example
insulator sequences or cis-acting regulatory elements, might
cause position e¡ects resulting in the impairment of RET ex-
pression. This mechanism would explain in part the propor-
tion of genetic disorders that are not associated with any
coding sequence mutations. Present results support the idea
that chromatin conformation and therefore the acetylation
pro¢le of this genomic domain exert a relevant control on
RET expression.
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